Project Grant R35GM165896
- The National Institute of General Medical Sciences awarded the University of Florida $387,845 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a personalized sepsis-risk engine using explainable artificial intelligence and in vitro validation. The research integrates multimodal electronic health record data with high-dimensional omics and mechanistic modeling to identify host pathways that convert neutropenic infection into sepsis and...
- The National Institute of General Medical Sciences awarded the University of Wisconsin–Madison $123,309 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational methods for improving sepsis diagnosis through plasma metagenomic sequencing. The research addresses the challenge of timely and accurate sepsis diagnosis in critically ill patients by analyzing microbial and host cell-free DNA (cfDNA) in blood plasma. Current diagnostic...
- The National Institute of General Medical Sciences awarded the Regents of the University of Michigan $411,475 under the Biomedical Research and Research Training program (CFDA 93.859) on September 1, 2026, to engineer a multiplexed biomaterial-based bioluminescent biosensor platform for real-time sepsis diagnosis and precision immunotherapy guidance. The recipient will develop a rapid ex vivo biosensor using biomaterial-immobilized complementation antibody pairs to dynamically sense proteomic...
- The National Institute of General Medical Sciences awarded Duke University $446,410 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, R01GM163225) to develop and validate statistical methods for identifying disease subtypes in patient populations, with application to sepsis. The project develops three classes of Bayesian statistical approaches designed to address limitations in standard clustering techniques: Bayesian multiview pyramids to handle...
- The National Institute of General Medical Sciences awarded Mayo Clinic Jacksonville $462,410 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to validate sepsis patient subphenotypes defined by lipoprotein and lipid metabolism profiles and assess their therapeutic utility in precision medicine approaches. The research addresses dysregulated lipoprotein and lipid metabolism in sepsis by validating two novel clinical subphenotypes—hypolipoprotein...
- The National Institute of General Medical Sciences awarded Baylor College of Medicine $181,440 on February 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the role of interleukin-1beta-fibrin(ogen) interaction in sepsis-induced coagulopathy. The award funds a five-year project running through January 31, 2031, performed in Houston, Texas. The research examines how interleukin-1 beta (IL-1B) bound to fibrin(ogen) alters clot characteristics and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $100,228 on February 13, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered cell-based systems that detect and treat sepsis through synthetic receptors targeting alarmin proteins S100A8 and S100A9. The project will explore two complementary cell engineering strategies: engineering cells to constitutively secrete therapeutics that modulate...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $192,330 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of intestinal microbiota in sepsis mortality. The project will elucidate mechanisms by which gut microbial dysbiosis influences sepsis outcomes through a five-year research effort running through May 31, 2031, at Yale's New Haven, Connecticut location. The research combines microbiota...
- The University of Florida, through its Division of Sponsored Research, received a $1.83 million Project Grant award dated September 5, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a three-year research project through August 31, 2028, investigating the role of NADPH oxidases (NOX) in sepsis-induced myopathy and impaired muscle regeneration. The...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $760,700 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the immune regulatory role of reactive oxygen species in sepsis. The research elucidates how reactive oxygen species modulate interleukin-1 beta bioactivity in sepsis and tests combined treatment with N-acetylcysteine and anakinra (an IL-1 receptor antagonist) to attenuate sepsis...
The National Institute of General Medical Sciences awarded the University of Florida $411,407 on August 15, 2026, to develop a bioanalytical platform for monitoring and modeling sepsis immunopathology under the Biomedical Research and Research Training program (CFDA 93.859). The funded research establishes an integrated platform to capture ultrasensitive, longitudinal biochemical monitoring of immune effectors in sepsis patients and develop dynamic disease models linking biochemical trends to host response trajectories. The work addresses the clinical challenge of identifying immunologic subtypes among unstable sepsis patients at high risk of death or chronic critical illness, where current care lacks granular biochemical datasets and disease progression models. The research encompasses three interconnected thrust areas: development of a bioanalytical platform engineered for ultrasensitive, continual biochemical monitoring in complex biofluids; creation of dynamic disease models to study sepsis immunopathology; and integration of monitoring and modeling capabilities. Work is performed at the University of Florida, Division of Sponsored Research in Gainesville, Florida. The award runs through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $411.4k | 8/6/26 |